Navidea Biopharmaceuticals Inc (NYSEAMERICAN:NAVB) was the target of a significant increase in short interest during the month of January. As of January 31st, there was short interest totalling 8,860,498 shares, an increase of 16.0% from the January 15th total of 7,639,128 shares. Approximately 5.8% of the company’s stock are short sold. Based on an average daily volume of 503,692 shares, the days-to-cover ratio is presently 17.6 days.
Navidea Biopharmaceuticals stock traded up $0.01 during midday trading on Monday, hitting $0.16. 467,600 shares of the stock were exchanged, compared to its average volume of 446,464. Navidea Biopharmaceuticals has a 52-week low of $0.10 and a 52-week high of $0.42.
Navidea Biopharmaceuticals Company Profile
Navidea Biopharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The company operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages; and NAV4694, a fluorine-18 labeled positron emission tomography imaging agent for use as an aid in the imaging and evaluation of patients with signs or symptoms of Alzheimers disease and mild cognitive impairment.
Further Reading: Return on Equity (ROE)
Receive News & Ratings for Navidea Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Navidea Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.